The Golden Lounge

[SSP]

$VYGR Voyager To Receive Up-front Consideration Of $175 Million Including A $39 Million Equity Investment, Up To $1.5 Billion In Potential Development Milestones, Additional Potential Commercial Milestones, Tiered Royalties On Net Sales, Program Funding, And An Option To Elect 50/50 Cost- And Profit-sharing In The U.s. For The Gba1 Program Following Phase 1 Readout

Under the terms of the agreement, Neurocrine Biosciences has agreed to pay Voyager $175 million up front, of which Neurocrine Biosciences has agreed to pay approximately $136 million in cash and to purchase approximately $39 million of newly issued equity in Voyager at a price of $8.88 per share, which represents a 50% premium to the average daily volume-weighted average price of Voyager’s stock over the 30 trading days prior to the execution of the transaction. In addition, Neurocrine Biosciences has agreed to fund all costs incurred under the collaboration, subject to the cost- and profit-sharing option terms below.

https://ir.voyagertherapeutics.com/news-releases/news-release-details/neurocrine-biosciences-and-voyager-therapeutics-enter-strategic